Published by - NITTE...DIABETIC WOUND HEALING: A REVIEW ON PHOTOTHERAPY Gayathri Baburaj* Diabetes Mellitus (DM) is a chronic metabolic disorder due to an absence of, insufficiency

1Pharmacy Practice Communicator

Paneer, Deralakatte, Mangaluru Ph: 0824 - 2203991 / 92 / 93 | Fax: 0824 - 2203992

Web: ngsmips.nitte.edu.in

Editor-in-chiefDr. C. S. Shastry, M. Pharm, Ph.D

Associate EditorDr. Uday Venkat Mateti, Pharm.D, Ph.D

Editorial board

Dr. Juno J. Joel, M. Pharm, MBA, Ph.D

Dr. Rajesh K.S., M. Pharm, Ph.D

Mr. Bharath Raj, M. Pharm

Mr. Nandakumar U. P, M. Pharm

Dr. Chinju S Chacko, Pharm.D

Dr. Vinay BC, Pharm.D

Department of Pharmacy Practice

B-2, Justice K. S. Hegde Charitable Hospital, Deralakatte, MangaluruPhone:0824–2204471, ext.: 2368- 69Email: [email protected]

For

Priv

ate

circ

ulat

ion

only

Contents

Molecular Genetics in Internet Addiction 2-3

Medication Reconciliation 4-6

Diabetic Wound Healing: A Review on Phototherapy 7-9

List of New Drugs approved by U.S. Food and Drug Administration 9

List of New Drugs approved by Central Drugs Standard Control Organization, India 10

Department of Pharmacy Practice News 11

Published by

March 2018March 2018March 2018


The origination of affordable computers, Internet access and its expanding popularity has led to apprehensions on its

extreme use.[1] Performing in a maladaptive pattern and high frequency, it could lead to psychological, family, and work [2]dysfunction. This will be the conception and can eventually lead to Internet addiction (IA).

The New York psychiatrist Ivan Goldberg was the first to suggest an addiction to the Internet, ironically. He later

elaborated a symptom list in 1995, for what he called ‘Internet Addiction Disorder’, analogous to the criteria for substance [3]dependence from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV).

In view of biopsychosocial perspective, addiction is the result of an interaction between many factors including biological

and/or genetic predisposition, psychological constitution (i.e. personality factors, unconscious motivations, attitudes,

expectations and beliefs, etc.), social environment and the nature of the activity itself. [4] The integration of all these

factors results in behaviours, which, if maladaptive and repetitive, have the potential to become an addiction

Though, no twin studies have investigated the heritability of IA, it has been revealed that another behavioral addiction,

pathological gambling, presents heritability estimates close to 50%.[5] If IA is deemed a behavioral addiction, it is

possible to imply a genetic susceptibility for the disorder.

Lee et al., observed the association between excessive Internet use, harm avoidance, and seroto-nin transporter

gene expression. The promoter region of the serotonin transporter gen (5HTTLPR) plays a role in the regulation of

serotonergic neurotransmission; the homozygous long allelic variant (L) is associated with higher concentrations of

serotonin mRNA and with greater rate of reuptake than variants containing the short allelic variant (S). This study found [6]the excessive Internet use group to have higher levels of harm avoidance and SS-5HTTLPR frequencies.

Another study assessed genetic polymorphisms of the dopaminergic system and temperament in adolescents with

excessive Internet videogame play. Han et al., tested for associations between re-ward-dependence scales and

frequencies of 3 dopamine polymorphisms: Taq1A1 allele of the do-pamine D2 receptor (DRD2 Taq1A1) and Val158Met

in the Catecholamine-O Methyltransferase (COMT) genes. The COMT gene has two allelic forms: the valine variant

(with high activity) and methionine variant (with low activity). The Taq1A1 allele has been associated with reduced

DRD2 density in the striatum, as well as suppressed dopaminergic signaling in the caudate nucleus, thala-mus, and

hippocampus. In this study, the Taq1A1 allele, low activity COMT alleles and higher re-ward-dependence scores were [7]significantly more prevalent in patients with excessive Internet vide-ogame play, relative to a control group.

Montag et al. studied the association between IA and the gene coding for the nicotinic acetylcholine receptor subunit

alpha 4 (CHRNA4). It has been shown that CHRNA4 impacts dopaminergic neurotransmission, domains of cognition,

attention and working memory. Furthermore, a specific CHRNA4 polymorphism (CC variant of rs1044396) has been

associated with significantly higher trait anxiety and smoking. Results showed an association between subjects with [8]occasional and frequent problems with the Internet and having the CC variant of the rs1044396 polymorphism.

The study of IA is still in its beginnings; however, it is clear that IA leads to dysfunction in a range of life activities, such

MOLECULAR GENETICS IN INTERNET ADDICTION

Dr. Juno J Joel*

as time management, social relationships, work duties, and can even affect biological domains.


References:

1. Shaw M, Black DW. Internet addiction: definition, assessment, epidemiology and clinical management. CNS Drugs.

2008; 22(5):353-65.

2. Cruzado Diaz L, Matos Retamozo L,Kendall Folmer R. Adicción a internet: Perfil clínico y epidemiológico de

pacientes hospitalizados en un instituto nacional de salud mental. Rev Med Hered 2006; 17: 196-205.

3. teWildt BT (2011) Internet Dependency: Symptoms, Diagnosis and Therapy. In: Virtual Worlds and Criminality. In

Cornelius, K. and Hermann, D. (eds). Springer Berlin Heidelberg, pp: 61-78.

4. Griffiths M. A ‘components’ model of addiction within a biopsychosocial framework. Jour-nal of Substance Use.

2005; 10: 191-197.

5. Slutske WS, Zhu G, Meier MH, Martin NG. Genetic and environmental influences on disor-dered gambling in men

and women. Arch Gen Psychiatry. 2010; 67: 624-630.

6. Lee YS, Han DH, Yang KC, Daniels MA, Na C, Kee BS, et al. Depression like characteris-tics of 5HTTLPR

polymorphism and temperament in excessive internet users. J Affect Dis-ord. 2008; 109: 165-169.

7. Han DH, Lee YS, Yang KC, Kim EY, Lyoo IK, Renshaw PF. Dopamine genes and reward dependence in adolescents

with excessive internet video game play. J Addict Med. 2007 1: 133-138.

8. Montag C, Kirsch P, Sauer C, Markett S, Reuter M. The Role of the CHRNA4 Gene in In-ternet Addiction: A Case-

control Study. J Addict Med. 2012; 6: 191-195.

*Assistant Professor, Department of Pharmacy Practice, Nitte Gulabi Shetty Memorial Institute of Pharmaceutical Sciences, Nitte

(Deemed to be University), Deralakatte, Mangaluru, Karnataka-575 018


MEDICATION RECONCILIATION

Jison Jose and Lija George *

Medication reconciliation is a formal process in which healthcare providers work together with patients, families and

care providers to ensure accurate and comprehensive medication information is communicated consistently across

transitions of care.[1] It is a formal process for creating the most complete and accurate list of a patient’s current

medications and comparing the list to those in the patient record or medication orders.

Medication reconciliation requires a systematic and comprehensive review of all the medications a patient is taking

to ensure that medications being added, changed or discontinued are carefully evaluated. It is a component of

medication management and will inform and enable prescribers to make the most appropriate prescribing decisions

for the patient.[1]

Transitions from one health care setting to other whether from an intensive care to a general ward or from a rehabilitation

facility to the patients’ home- increase the risks of adverse drug events and can contribute to avoidable hospital

visits. For instance, incomplete or inaccurate medication information can introduce changes to patients’ outpatient

medication regimens that were not intended by hospital based physicians. Two common unintended medication

changes are omissions-preadmission medications are omitted from hospital orders and therefore not continued after

discharge and commissions- previous medications that patients discontinued prior to admission are inadvertently

re- initiated in the hospital and therefore continued upon discharge. [2]

• Medication reconciliation is a requirement for meeting the Safety and Quality in Healthcare’s Medication Safety

Standard.

• It is recognised as a key strategy towards improving medication safety thereby reducing harm from medication

misadventure

• It is conducted to ensure patients receive all intended medicines and avoid errors of transcription, omission,

duplication of therapy, drug-drug and drug-disease interactions.

• It should be delivered to all patients but in particular those identified at risk: in transition, or as a result of changes

in their medical condition.[3]

Medication reconciliation is important at care transition points: Admission to the Hospital, Transfers within the Hospital

(intra hospital transfer), and Discharge from the Hospital. [4]

[5]Fig. 1: Steps in Medication Reconciliation


Role of Pharmacist in Medication Reconciliation

Specifically, pharmacists’ responsibilities were described as including but not being limited to

• Providing leadership in designing and managing patient-centred medication reconciliation systems,

• Educating patients and health care professionals about the benefits and limitations of the medication reconciliation

process, and

• [2]Serving as patient advocates throughout transitions of care.

Beyond active participation in medication reconciliation activities, pharmacists have five fundamental functions

in medication reconciliation: developing policies and procedures regarding medication reconciliation processes,

implementing and continuously improving those processes, training and assuring the continuing competency of those

involved in medication reconciliation, providing operational and therapeutic expertise in the development of information

systems that support medication reconciliation, and advocating for medication reconciliation programs in the community.[6]

Guiding principles for implementation of medication reconciliation

1. An up-to-date and accurate patient medication list is essential to ensure safe prescribing in any setting.

2. A formal structured process for reconciling medications should be in place cross all interfaces of care.

3. Medication reconciliation on admission is the foundation for reconciliation throughout the episode of care.

4. Medication reconciliation is integrated into existing processes for medication management and patient flow.

5. The process of medication reconciliation is one of shared accountability with staff aware of their roles and

responsibilities.

6. Patients and families are involved in medication reconciliation.

7. [5]Staff responsible for reconciling medicines are trained to take a BPMH and reconcile medicines.

The practical challenges encountered in the implementation of medication reconciliation are:

ü Substantial underestimation of the time and resources required to implement medication reconciliation.

ü Resistance from front-line staff impacts on work load and work flow (physicians sometimes resisted even

independent of such impacts).

ü A lack of implementation/change management experience.

ü Turnover on the core implementation team.

ü Limited resources for ongoing education and support to sustain the implementation.

ü [2]Too rapid implementation, as a result of pressure due to accreditation, resulting in poorly configured process.


* Pharm.D Intern, Department of Pharmacy Practice, Nitte Gulabi Shetty Memorial Institute of Pharmaceutical Scienc-es, Nitte

[1]Fig. 2: Overview of Medication Reconciliation

References:

1.

(Deemed to be University), Deralakatte, Mangaluru, Karnataka - 575 018

Medication Reconciliation in Acute Care Getting Started Kit - The Institute for Safe Medication Practices Canada (ISMP Canada). Available from: https://www.ismp-canada.org/download/MedRec/Medrec_AC_English_GSK_V3.pdf. [Last Accessed on March 10, 2018]

2. Fernandes O, Shojania KG. Medication Reconciliation in the Hospital: What, Why, Where, When, Who and How?. Healthcare Quarterly 2012; 15:42-49.

3. Medication reconciliation. How do pharmacists add value? Available from: https://www.shpa.org.au/sites/default/files/uploaded-content/website-content/Fact-sheets-position-statements/medrecv2.pdf. [Last Accessed on February 10, 2018]

4. Medication Safety Reconciliation Tool Kit, North Carolina Center for Hospital Quality and Patient Safety. Available from: https://www.ncqualitycenter.org/wp-content/uploads/2013/01/MRToolkit.pdf. [Last Accessed on February 10, 2018]

5. The High5s Project – Standard Operating Protocol for Medication Reconciliation. Available from: http://www.who.int/patientsafety/implementation/solutions/high5s/h5s-sop.pdf. [Last Accessed on February 11, 2018]

6. ASHP statement on the pharmacist’s role in medication reconciliation. Am J Health Syst Pharm. 2013;70(5):453-6.


DIABETIC WOUND HEALING: A REVIEW ON PHOTOTHERAPY

Gayathri Baburaj*

Diabetes Mellitus (DM) is a chronic metabolic disorder due to an absence of, insufficiency in, or resistance to insulin. Complications arise as a result of elevated glucose levels and protein glycation and include cardiovascular disease, retinopathy, nephropathy, angiopathy, and neuropathy. Patients are more likely to have foot problems due to blood vessel and nerve damage and often suffer from sensory loss. Small sores can develop into deeper ulcers which become slow to heal, and further complications such as infection arise which often necessitate amputation due to the spread of infection to the underlying tissue and bone.[1] Management of the diabetic foot includes both local (treating of the diabetic foot) and systemic (glycemic control).

Phototherapy is a relatively new, non-invasive, and pain-free treatment method, which promotes the ulcer repair process through multiple mechanisms such as increased cell growth and vascular activity. Phototherapy, or low-level laser therapy (LLLT), is a therapeutic treatment modality that has been found to enhance wound healing. Its therapeutic

[2]properties have been determined by means of in vitro, in vivo and animal studies.

Phototherapy

Phototherapy, also known as photobiomodulation, low-level laser therapy (LLLT), involves the application of light (often laser light of a specific wavelength or a light emitting diode, LED) to stimulate cellular processes. The exact mechanisms of action following laser irradiation are not well understood, but most studied is that, Laser light is absorbed by chromophores in the cell, mitochondria in the case of visible red light. This leads to an increase in adenosine triphosphate (ATP), reactive oxygen species (ROS), nitric oxide (NO), and intracellular calcium (iCa2+).There is an activation of transcription factors which get translocated to the nucleus and activate gene transcription. This leads to

[1 ]increased cell survival and wound healing.

Effect of LLLT on diabetic ulcers

Several studies have acknowledged that LLLT stimulates angiogenesis and microcirculation and promotes vasodilation, thereby improving blood circulation and reducing tissue damage that is caused by ischaemia.

In vitro studies

A review of the literature that was published between 2002 and 2009 by Peplow et al showed that there was a clear positive effect on cells when LLLT was applied. LLLT stimulated cellular proliferation in a wide variety of cell types, including fibroblasts, endothelial cells, smooth muscle cells, stem cells, osteoclasts, osteoblasts and

[3]keratinocytes. AlGhamdi et al conducted a review of the literature and suggested that a dose of 0.5-4.0 J/cm2, and a wavelength ranging from 600-700 nm, were the most beneficial and helpful in enhancing cellular proliferation. At the correct laser parameters, LLLT has been shown to positively stimulate diabetic-wounded fibroblast cells. An increase in viability, proliferation, ATP, growth factors, cytokines and nitric oxide results, as well as a decrease in cellular damage and proinflammatory cytokines.[4] A study conducted by Gavish et al on smooth muscle cells demonstrated that LLLT stimulated proliferation and collagen synthesis, and modulated equilibrium between the degradation and synthesis of the extracellular matrix; a very important aspect in diabetic wound healing. LLLT has a direct influence on the

[5]mitochondria of irradiated cells.

In vivo studies

Accelerated wound healing has been observed in vivo following phototherapy. It resulted in increased rates of epithelisation in human studies and the promotion of connective tissue stability. According to a study that was conducted by Schindl et al, phototherapy improved microcirculation at the irradiated site, and caused a systemic effect on microcirculation, thereby improving the skin circulation.[6] A study conducted on 30 Egyptian patients with diabetic-linked skin lesions (dryness, hair loss, infections, itching, eczema and nail changes) showed that combined irradiation of the affected area with visible red and infrared lasers improved blood flow and partially reversed the condition in the affected area.[6] Study conducted by Minatel et al found that phototherapy promotes tissue granulation and rapid healing of diabetic ulcers. Studies prove that medium- and large-sized ulcers that were treated with phototherapy had a 40%

[7]faster healing rate per month.


Animal studies

Several studies have been conducted on animals with diabetes to evaluate the effects of phototherapy on the healing process of diabetic wounds. Positive results have been shown in wound healing in mice with diabetes. Kawalec et

[8]al and Agnol et al[9] showed that LLLT has the ability to significantly reduce the size of a wound that was inflicted in diabetic mice and rats respectively.[2] Al-Watban demonstrated that streptozotocin-induced diabetic rat burns and wounds responded favourably to irradiation at a wavelength of 633 nm. Rabelo et al irradiated full-thickness wounds in streptozotocin-induced diabetic rats (632.8 nm). 10 They found that irradiation promoted efficient wound healing at a faster rate than in control rats. [2] It has been shown that a single treatment of LLLT (wavelength of 660 nm, fluence of 4 J/cm2) is enough to accelerate the inflammatory phase, angiogenesis and leukocyte chemotaxis in burn wounds on the backs of rats. Not all studies have shown positive effects. Abdi et al found that laser irradiation (632.8 nm) did not

[2]enhance bone repair of a partial transversal standardised osteotomy in streptozotocin-induced diabetic rats.

Effect of LLLT on infection and inflammation

Different wavelengths are used for different applications in phototherapy. Light in the visible red to near-infrared spectrum has been shown to be absorbed by cytochrome c oxidase, while light in the blue spectrum is absorbed by flavins. Blue light has been shown to have bactericidal effects. Enwemeka et al established that blue light (470 nm) was able to kill

[2]methicillin resistant Staphylococcus aureus (MRSA) in vitro. This is an important breakthrough, since the treatment of MRSA is extremely difficult. A number of other studies have found that blue light is bactericidal to Propionibacterium acne, S. aureus and Pseudomonas aeruginosa. Lipovsky et al revealed that high-intensity visible light in the range of 400- 1000 nm was bactericidal to several pathogenic bacteria, namely S. aureus, P. aeruginosa, Escherichia coli

[11]and Serratia marcescens. Ankri et al showed that a wavelength of 480 nm LLLT was optimal when treating infected wounds and should be used first, followed by irradiation at 730 nm to enhance wound closure.[12] Xavier et al showed that phototherapy reduces inflammation in collagenase-induced tendinitis in rats. Postirradiation (LED 880 nm), there was a reduction in the amount of inflammatory cells, as well as a decrease in inflammatory cytokines interleukin-1 beta

[13](IL-1b), IL-6, tumour necrosis factor alpha (TNF-a) and cyclooxygenase 2.

Conclusion

Phototherapy or LLLT may be considered from a range of alternative treatment options, such as biological therapies, hyperbaric oxygen and negative-pressure therapy, which help to enhance the wound healing process. However, in practice, the management of diabetic lower limb ulcerations depends on clinicians and available resources. It is important to note that new technologies are not optimally effective unless they are coupled with appropriate overall wound management.

References

1. Houreld NN. Review article shedding light on a new treatment for diabetic wound healing: A review on phototherapy, Sci. World J, 2014: 1-4.

2. Nteleki B. The use of phototherapy in the treatment of diabetic ulcers, Journal of Endocrinology, Metabolism and Diabetes of South Africa, 17(3): 128-132.

3. Peplow PV, Chung TY, Baxter GD. Laser photobiomodulation of proliferation of cells in culture: a review of human and animal studies. Photomed Laser Surg. 2010; 28(Supplement 1):S3-S40.

4. AlGhamdi KM, Kumar A, Moussa NA. Low-level laser therapy: a useful technique for enhancing the proliferation of various cultured cells. Lasers Med Sci. 2012; 27(1): 237-249.

5. Gavish L, Perez L, Gertz SD. Low-level laser irradiation modulates matrix metalloproteinase activity and gene expression in porcine aortic smooth muscle cells. Lasers Surg Med. 2006; 38(8): 779-786.

6. Schindl A, Heinze G, Schidl M, et al. Systemic effects of low-intensity laser irradiation on skin microcirculation in patients with diabetic microangiopathy. Microvasc Res. 2002; 64(2): 240-246.

7. Minatel DG, Frade MAC, Franca SC, Enwemeka CS. Phototherapy promotes healing of chronic diabetic leg ulcers that failed to respond to other therapies. Lasers Surg Med. 2009; 41(6): 433-441.

8. Kawalec JS, Pfennigwerth TC, Hetherington VJ, et al. A review of lasers in healing diabetic ulcers. The Foot. 2004; 14(2):68-71.


NEW DRUGS APPROVED BY USA FOOD AND DRUGADMINISTRATION (FDA)


(JANUARY – MARCH 2018)

Arati Pal*

9.


Agnol M, Nicolau R, De Lima C, Munin E. Comparative analysis of coherent light action (laser) versus non-coherent light (light-emitting diode) for tissue repair in diabetic rats. Lasers Med Sci. 2009; 24(6):909-916.

10. Rabelo SB, Villaverde AB, Nicolau R, et al. Comparison between wound healing in induced diabetic and nondiabetic rats after low-level laser therapy. Photomed Laser Surg. 2006; 24(4):474-479.

11. Lipovsky A, Nitzan Y, Lubart R. A possible mechanism for visible light-induced wound healing. Lasers Surg Med. 2008;40(7):509-514.

12. Ankri R, Lubart R, Taitelbaum H. Estimation of the optimal wavelengths for laserinduced wound healing. Lasers Surg Med. 2010;42(8):760-764.

13. Xavier M, David DR, De Souza RA, et al. Anti-inflammatory effects of low-level light emitting diode therapy on Achilles tendinitis in rats. Lasers Surg Med. 2010; 42(6):553-558.

Specialty Drug Name Brand Name

Company Name Uses Approved (Month, Year)

Gastroenterology Lutetium Lu 177 dotatate

Lutathera Advanced Accelerator Applications

For the treatment of gastroenteropancreatic neuroendocrine tu-mors

January 2018

Infections and Infectious Diseases

Bictegravir/ emitricitabine/

tenofovir alafenamide

Biktarvy Gilead For the treatment of HIV-1 infection in adults

February 2018

Ibalizumab- uiyk

Trogarzo TaiMed Biologics For the treatment of multidrug resistant HIV-1

infection

March 2018

OncologyApalutamide Erleada Janssen

Oncology For the treatment of prostate

cancer February

2018

Pulmonary/Respiratory

Diseases

Tezacaftor/ ivacaftor

Symdeko Vertex For the treatment of cystic fibrosis

February 2018

Reference: http://www.centerwatch.com/drug-information/fda-approved-drugs/. (Last accessed on 02 April, 2018)




NEW DRUGS APPROVED BY CENTRAL DRUGS STANDARD CONTROL ORGANIZATION (CDSCO), India

(JANUARY – MARCH 2018)Anila Varkey*

Drug Name Strength Indication Date of issue

Tenofovir Alafenamide

Hemifumarate Bulk & Emtricitabine

+ Tenofovir Alafenamide

200mg/200mg+

10/25 mg Tablets

In combination with other antiretroviral agents for treatment of Human Immunodeficiency Virus type-1 (HIV-1) infection in adults and adolescents with aged 12 years and older.

10th January 2018

Clofarabine Bulk & Injection

20 mg/20ml vial For the treatment of patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. This indication is based upon response rate.

16th January 2018

Denaverine Hydrochloride Injection (Vet.)

40 mg Cattle : Facilitation of parturition in heifers; activation of cattle : Facilitation of parturition in heifers; activation of interrupted parturitions; insufficient opening of the soft birth canal; narrowness of the cervix of first and second degree after correction of uterine torsions; improvement of the conditions for foetotomy; regulation of labour contractions of the uterusDogs: Activation of Interrupted parturition

16th January 2018

Netupitant + Palonosetron

Capsule

300 mg+0.5 mg For the prevention of acute and delayed nausea and vomiting associated with highly emetogenic Cisplatin-based cancer chemotherapy.For the prevention of acute and delayed nausea and vomiting associated with moderate emetogenic cancer chemotherapy in adult.

20th February

2018

Fipronil + Permethrin

6.1 % m/v+54.5% m/V spot on solution for Dog

In dogs, to be used against infestations with fleas and /or ticks when repellent (anti feeding) activity is necessary against sand-files and/ or mosquitoes.

20th February 2018

Praziquantel + Abamectin

0.0065 g +0.00025 g tablets for cat (Vet)

In infestation of cats with endoparasites tapeworms (teniae), flukes,

roundworms (nematodes); with ectoparasites- lice, fleas, pasture ticks,

notedric mange (feline scabies), “walking” dandruff (cheyletiellosis)

and other mange, and particularly in cases of complex endo and

ectoparasitic invasion.

20th February 2018

Cadexomer Iodine Bulk & Powder 100 % w/w or

Cadexomer Iodine Ointment (contains 0.9% w/v iodine)

contain 0.9 % w/v Iodine or 500mg

For the treatment of chronic exuding wounds such as leg ulcers, pressure ulcers and diabetes ulcers infected traumatic and surgical wounds

05th March 2018

Dalfampridine Bulk & Film

coated extended release tablet

10mg For treatment to improve walking in patients with multiple sclerosis (MS)

12th March 2018

Ulipristal Acetate 5mg For the pro-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age and intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age

14th March 2018

Reference: http://www.cdsco.nic.in/forms/list.aspx?lid=2034&Id=11 (Last accessed on 02 April, 2018)




Nitte (Deemed to be University) sponsored One Day Seminar on “Career Advancement through Professional Development and Personal Excellence” was organized by the NGSM Institute of Pharmaceutical Sciences, Paneer, Deralakatte, Mangaluru on 12th March 2018 at University Auditorium, Paneer Campus, Deralakatte, Mangaluru, Karnataka. The aim of seminar is to provide a platform for students, researchers, marketing & IT professionals, academicians, doctors, nurses, pharmacists, industry representatives and heath care professionals to strengthen the necessary skills and knowledge for career advancement to carry out the role as effectively throughout the working life.

The seminar received an overwhelming response with 181 students, research scholars and staff from Nitte (Deemed to be University) constituent colleges, Yenepoya University, Mangalore University, Mangaluru, Pariyaram Medical College, Pariyaram, Kerala were attended in the one day seminar.

The seminar was inaugurated by the Chief Guest, Prof. Vinod Aranha, Director, Nitte Institute of Architecture, Presiding Officer, Dr. M.S. Moodithaya, Honourable Pro-Vice Chancellor of Nitte (Deemed to be University), Prof. (Dr.) C.S. Shastry, Principal, NGSMIPS, Dr. R. Narayana Charyulu, Vice-Principal, NGSMIPS, Mr. M. Vijay Kumar, Organising Secretary and Dr. Uday Venkat Mateti, Co-Organising Secretary were presided over the function.

Prof. (Dr.) C.S. Shastry welcomed the gathering and introduced Guests and Resource Persons. Presiding over the function, Prof. Vinod Aranha and Dr. M.S. Moodithaya addressed the gathering highlighted the importance of the seminar. Mr. M. Vijay Kumar, Organising Secretary, delivered the vote of thanks.

DEPARTMENT OF PHARMACY PRACTICE NEWS

One Day Seminar on“CAREER ADVANCEMENT THROUGH PROFESSIONAL

DEVELOPMENTAND PERSONAL EXCELLENCE”

12th March 2018

During the seminar, three scientific sessions were conducted on the theme of “Career Advancement through Professional Development and Personal Excellence”.

Prof. Raghothama Rao, Director, Manas Centre for Training and Development Chairman, Karnataka Academy for Television Arts, Bengaluru delivered a talk on “Personal Excellence”. In his talk he discussed about the key points to success in personal life which helps to balance both personally and professionally to succeed, he explained the whole thing of the topic under three heads like lighter way brighter way and tighter way.

Dr. LS Ganesh, Professor, Dept. of Management Studies, IIT Madras, Chennai delivered a talk on

“Professional Development for Productive Career”. In his talk he discussed how to develop the career with professional development and he knocked the important issues in India with respect to employment and implications. He just gave a statistics of the output of graduates and the employment available to them which is a need of the day.

Dr. Sreedhar D , Associate Professor & HOD, Dept. of Pharmacy Management, MCOPS, MAHE, Manipal delivered a talk on “Time Management”. In his talk he discussed about various types of time, time robbers and time management matrix and time allotment.

The interactive scientific sessions allowed students, research scholars and faculty members to broaden their interest and knowledge in different aspects of “Career Advancement through Professional Development and Personal Excellence”

Poster Presentations in 3rd International CPCON

Pharm.D VI year (Ms. Angel Maria, Ms. Ansha Mariya, Ms. Arati Pal, Ms. Jismi Joseph, Ms. Namita Anchan, Ms. Sneha Mathew) and II M Pharm (Ms. Angel Rose) students of Dept. of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences have been Participated and Pre-sented the Papers in the “3rd International Conference on Clinical Pharmacy” held from 21 - 22 January 2018, Manipal University, Manipal.

Nitte Institutions

Health Science Institutions, Hospitals and Research Centres

Engineering Institutions

18. Nitte Mahalinga Adyanthaya Memorial Institute of Technology, Nitte

19. Nitte Meenakshi Institute of Technology, Bengaluru

20. Nitte Institute of Architecture, Mangaluru

1. K.S. Hegde Medical Academy, Mangaluru

2. A.B. Shetty Memorial Institute of Dental Sciences, Mangaluru

3. Nitte Gulabi Shetty Memorial Institute of Pharmaceutical Sciences,

Mangaluru

4. Nitte Usha Institute of Nursing Sciences, Mangaluru

5. Nitte Institute of Physiotherapy, Mangaluru

6. Nitte Institute of Medical Laboratory Sciences, Mangaluru

7. Nitte Institute of Speech and Hearing, Mangaluru

8. Justice K. S. Hegde Charitable Hospital, Mangaluru

9. Nitte Meenakshi Institute of Craniofacial Surgery, Mangaluru

10. Leela Narayana Shetty Memorial Cancer Institute, Mangaluru

11. Nitte-Gajria Hospital, Karkala

12. Kshema-IVF: Fertillity & Reproductive Medicine Centre, Mangaluru

13. Nitte Rural Psychiatry Centre, Nitte.

14. Kowdoor Gopal Hegde & Smt. Manorama Hegde Hospital, Bailur.

15. Nitte University Centre for Science Education & Research (NUCSER),

Mangaluru

16. Nitte University Centre for Animal Research & Experimentation (NUCARE),

Mangaluru

17. Nitte University Centre for Stemcell Research & Regenerative Medicine

(NUCSReM), Mangaluru

Management Institutions

21. Justice K. S. Hegde Institute of Management (Dept. of Nitte

Management Studies, NMAMIT, Nitte)

22. Nitte School of Management, Bengaluru

23. Sarosh Institute of Hotel Administration, Mangaluru

24. Nitte Institute of Banking & Finance, Mangaluru

25. Nitte Institute Communication, Mangaluru

Technical Instituions

26. Nitte Rukmini Adyanthaya Memorial Polytechnic, Nitte

27. Mulki Ramakrishna Punja Industrial Training Institute, Thokur

Science and Commerce Institutions

28. Dr. Nitte Shankara Adyanthaya Memorial First Grade College, Nitte

29. Dr. Nitte Shankara Adyanthaya Memorial First Grade College, Bengaluru

30. Dr. Nitte Shankara Adyanthaya Memorial Pre-University College, Nitte

31. Dr. Nitte Shankara Adyanthaya Memorial Pre-University College, Mangaluru

32. Dr. Nitte Shankara Adyanthaya Memorial Pre-University College, Bengaluru

Schools

33. Dr. Nitte Shankara Adyanthaya Memorial Senior Secondary School, Nitte

34. Dr. Mundkur Ramanna Shetty Memorial English Medium High School,

Thokur

35. Nitte International School, Bengaluru

36. Dr. Nitte Shankara Adyanthaya Memorial Higher Primary School, Bolakodi

Satellite Health Centres:

Bailur | Bellikoth | Bengre Dabbekatte | Farangipet | Hejamadikodi |

Kadri | Karkala | Mangalagangothri | Madikeri | Mukka | Mulki |

Mundkur | Nada | Nitte | Sasihithlu | Sringeri | Subrahmanya |

Thalipadi

Pharmacy Practice Communicator

Documents

Published by - NITTE...DIABETIC WOUND HEALING: A REVIEW ON PHOTOTHERAPY Gayathri Baburaj* Diabetes Mellitus (DM) is a chronic metabolic disorder due to an absence of, insufficiency